Adage Capital Partners Gp, L.L.C. Amylyx Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 5,697,605 shares of AMLX stock, worth $27.9 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
5,697,605Holding current value
$27.9 Million% of portfolio
0.04%Shares
8 transactions
Others Institutions Holding AMLX
# of Institutions
148Shares Held
73MCall Options Held
148KPut Options Held
98.7K-
Perceptive Advisors LLC New York, NY7.87MShares$38.6 Million1.17% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$29.1 Million5.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.12MShares$20.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.08MShares$15.1 Million0.01% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.93MShares$14.4 Million0.47% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $287M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...